Evaluation of commercial potential of a low cost kit based on DNA nanoswitches f...
Evaluation of commercial potential of a low cost kit based on DNA nanoswitches for the single step measurement of diagnostic antibodies
"Antibodies are among the most widely monitored class of diagnostic biomarkers. Immunoassays market now covers about 1/3 of the global market of in-vitro diagnostics (about $50 billion). However, current methods for the detection...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RTC2019-007075-1
DROPLITE, Nueva prueba rápida de detección de hormonas femen...
227K€
Cerrado
MAT2012-38573-C02-01
PLATAFORMAS DE DIAGNOSTICO UNIVERSAL BASADAS EN NANOPARTICUL...
121K€
Cerrado
TEC2012-34280
INTEGRACION LAB-ON-A-CHIP DE DISPOSITIVOS BIOFOTONICOS PARA...
138K€
Cerrado
ODASMIR
Origami-DNA/AgNCs Sensor for Detection of miRNAs
181K€
Cerrado
2-NanoSi
Ratiometric FRET Based Nanosensors for Trypsin Related Human...
150K€
Cerrado
MAT2011-29335-C03-01
PLATAFORMAS DE DIAGNOSTICO UNIVERSAL BASADA EN NANOPARTICULA...
30K€
Cerrado
Información proyecto AB-SWITCH
Duración del proyecto: 19 meses
Fecha Inicio: 2016-12-02
Fecha Fin: 2018-07-31
Descripción del proyecto
"Antibodies are among the most widely monitored class of diagnostic biomarkers. Immunoassays market now covers about 1/3 of the global market of in-vitro diagnostics (about $50 billion). However, current methods for the detection of diagnostic antibodies are either qualitative or require cumbersome, resource-intensive laboratory procedures that need hours to provide clinicians with diagnostic information. A new method for fast and low-cost detection of antibodies will have a strong economic impact in the market of in-vitro diagnostics and Immunoassays.
During our ERC Starting Grant project ""Nature Nanodevices"" we have developed a novel diagnostic technology for the detection of clinically relevant antibodies in serum and other body fluids. The platform (here named Ab-switch) supports the fluorescent detection of diagnostic antibodies (for example, HIV diagnostic antibodies) in a rapid (<3 minutes), single-step and low-cost fashion.
The goal of this Proof of Concept project is to bring our promising platform to the proof of diagnostic market and exploit its innovative features for commercial purposes. We will focus our initial efforts in the development of rapid kits for the detection of antibodies diagnostic of HIV. We will 1) Fully characterize the Ab-switch product in terms of analytical performances (i.e. sensitivity, specificity, stability etc.) with direct comparison with other commercial kits; 2) Prepare a Manufacturing Plan for producing/testing the Ab-switch; 3) Establish an IP strategy for patent filing and maintenance; 4) Determine a business and commercialization planning."